Latest news for Immunome (NASDAQ:IMNM) Stock

Immunome

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.

defence analysts

News

Initiation

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

CDTX

CYTK

FLUT

IMNM

This Cytokinetics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Stocks Photo by Jirapong Manustrong on Shutterstock

Long Ideas

Insider Trades

ACDC

ASTC

Over $13M Bet On ProFrac Holding? Check Out These 4 Stocks Insiders Are Buying

Bull and bear stock market index

Analyst Color

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Broad U.S. Equity ETFs

Commodities

Economics

Federal Reserve

Intraday Update

ETFs

$BTC

AMZN

CATX

SPDR Dow Jones Industrial Average ETF Trust

GOLD

NKLA

SMTC

XLRE

In the final session of the short trading week leading up to Easter festivities, U.S. equity indices held steady, reflecting some setbacks in market expectations regarding interest rate reductions.

Stocks Pause As Traders Reassess Interest Rate Path, Gold Makes New Highs, Bitcoin Rebounds: What&#39;s Driving Markets Thursday?

Immunome Inc

TD Cowen analyst Max Rakhlenko maintains Williams-Sonoma (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) with a Buy and raises the price target from $165 to $195.

Price Target

TD Cowen Maintains Buy on Williams-Sonoma, Raises Price Target to $195

Mizuho analyst Anthony Crowdell maintains AES (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>) with a Outperform and lowers the price target from $24 to $16.

Mizuho Maintains Outperform on AES, Lowers Price Target to $16

On Thursday, the Cellular, Tissue, and Gene Therapies Advisory Committee will discuss AstraZeneca Plc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) supplemental biologics license application for Andexxa (coagulation factor Xa (recombinant), inactivated -zhzo), for patients treated with rivaroxaban or apixaban when reversal of anticoagulation is needed due to life-threatening <a href="https://www.benzinga.com/general/health-care">or uncontrolled bleeding.</a>
The FDA initially granted accelerated approval of <a href="https://www.fda.gov/advisory-committees/advisory-committee-calendar/cellular-tissue-and-gene-therapies-advisory-committee-november-21-2024-meeting-announcement-11212024">Andexxa</a>, a recombinant modified human factor Xa (FXa) protein, in 2018 based on the change from baseline in anti-activated FXa (anti-FXa) activity, as a surrogate endpoint reasonably likely to predict clinical benefit as provided for in 21 CFR 601.41.
AstraZeneca was required to conduct a randomized controlled trial to verify and describe the clinical benefit of Andexxa, due to uncertainty as to the relation of the surrogate endpoint to clinical benefit and the observed clinical benefit to ultimate outcomes in the indicated population. In January 2024, the company submitted a supplemental Biologics Licensing Application for Andexxa with the results of the ANNEXA-I trial to fulfill this requirement.
Before the meeting, the FDA panel released <a target="_blank" href="https://www.fda.gov/media/183674/download" rel="noreferrer noopener">brief</a> documents highlighting some safety issues and other concerns.
"Although andexanet showed superiority of the primary efficacy endpoint over UC [usual care] within the PEP [primary efficacy population], the superior efficacy at 12 hours did not predict longer-term benefit," FDA said.
The major safety findings included a doubling of the rate of thromboses and thrombosis-related deaths at Day 30 in the andexanet arm compared with UC.
The major topics for discussion:
<ul>
<li>ANNEXA-I demonstrated an increased incidence of thrombosis (14.6% versus 6.9%) and thrombosis-related deaths at Day 30 (2.5% versus 0.9%) in the andexanet arm compared with the UC arm, respectively. These findings raise concerns regarding whether the serious risks of treatment with andexanet are acceptable in the indicated population.</li>
<li>While the primary efficacy endpoint in ANNEXA-I was met, the treatment difference across arms appears to be primarily driven by one of three components of the composite endpoint, namely the volume of hematoma at 12 hours, while other clinically meaningful endpoints were not different between the two arms. These findings raise the question as to whether the benefit demonstrated in ANNEXA-I outweighs the serious risks.</li>
</ul>
The document highlighted, &#8220;Treatment with andexanet demonstrated a statistically significant improvement in hemostasis compared to UC (andexanet: 65.7% versus UC: 53%). The observed treatment difference between arms appears to be primarily driven by hematoma volume, with more patients in the andexanet arm than UC arm experiencing a ≤35% increase from baseline in hematoma volume at 12 hours (74% versus 60%).&#8221;
Hematoma is a blood collection that pools outside blood vessels, usually caused by an injury or surgery.
Price Action: AZN stock is up 0.97% at $63.82 at last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42110605/deere-q4-earnings-beats-expectations-steep-sales-drop-margins-squeeze-more" target="_blank" rel="noreferrer noopener">Deere Q4 Earnings: Beats Expectations, Steep Sales Drop, Margins Squeeze &amp; More</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Biotech

Health Care

General

AstraZeneca's Andexxa Faces FDA Scrutiny Over Effectiveness, Safety Concerns

WIIM

SWVL

Swvl Holdings shares are trading higher after the company announced it signed a three-year contract with G4S in Saudi Arabia to provide SaaS-based mobility solutions.

Mizuho analyst Vijay Rakesh maintains NVIDIA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) with a Outperform and raises the price target from $165 to $175.

NVDA

Mizuho Maintains Outperform on NVIDIA, Raises Price Target to $175

<a href="https://www.justice.gov/usao-cdca/pr/texas-based-oil-and-gas-company-phillips-66-indicted-alleged-violations-clean-water#:~:text=LOS%20ANGELES%20%E2%80%93%20A%20federal%20grand,the%20Los%20Angeles%20County%20sewer" title="https://www.justice.gov/usao-cdca/pr/texas-based-oil-and-gas-company-phillips-66-indicted-alleged-violations-clean-water#:~:text=LOS%20ANGELES%20%E2%80%93%20A%20federal%20grand,the%20Los%20Angeles%20County%20sewer">https://www.justice.gov/usao-cdca/pr/texas-based-oil-and-gas-company-phillips-66-indicted-alleged-violations-clean-water#:~:text=LOS%20ANGELES%20%E2%80%93%20A%20federal%20grand,the%20Los%20Angeles%20County%20sewer</a>

Legal

'Texas-Based Oil-and-Gas Company Phillips 66 Indicted for Alleged Violations of Clean Water Act Stemming from Wastewater Discharge' - CA Attorney

Reaffirms Revenue Recognition Impact of $4 to $6 million
Ending Cash Position of Approximately $56 Million as of September 30, 2024, Consistent with Internal Forecasts
Announces Remedial Actions and Organizational Changes, Including the Resignation of the Company's Chief Financial Officer
Hires Leading Business Advisory Firm, AlixPartners, to Provide Interim Finance and Accounting Resources
Evolv Technology ("Evolv" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>), a leading security technology company pioneering AI-based solutions designed to create safer experiences, today announced the results of the internal investigation previously disclosed on October 25, 2024, into certain sales practices that impacted revenue recognition and other metrics.

Earnings

Management

EVLV

Earlier Reported, Evolv Technology Announces The Results Of Its Internal Investigation; Reaffirms Revenue Recognition Impact Of $4M-$6M; Ending Cash Position Of ~$56M As Of September 30, 2024, Consistent With Internal Forecasts; Mark Donohue, The Company's CFO And Principal Financial Officer And Principal Accounting Officer, Has Resigned; Hires Leading Business Advisory Firm, AlixPartners, To Provide Interim Finance And Accounting Resources

FLYE

Fly-E Group shares are trading lower after the company reported a year-over-year decrease in Q2 financial results.

Kyndryl shares are trading higher after the company's board authorized a $300 million share repurchase program.

Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) has expanded its collaboration with XPEL, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XPEL#NASDAQ">XPEL</a>) to offer a new customization program for its R1T and R1S electric vehicle owners<a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42096490/xpel-and-rivian-expand-collaboration-with-new-ppf-and-window-film-program" rel="noreferrer noopener"> in the U.S. and Canada.</a>
The program, available through Rivian&#8217;s Gear Shop, allows owners to order XPEL&#8217;s Paint Protection Film (PPF) and Window Film products directly, with set pricing and easy installation booking through a local XPEL Certified Rivian Network Partner.
Rivian owners can now protect their vehicles with XPEL&#8217;s ULTIMATE PLUS Paint Protection Film, which guards against scratches, chips, and stains while offering a self-healing finish. The film also resists UV yellowing to maintain clarity.
Additionally, the PRIME Window Film provides added privacy, heat rejection, and UV protection, blocking 99% of harmful UV rays. Owners can choose from various window film tints, including PRIME CS, XR, and XR PLUS.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/11/42113449/natural-gas-prices-spike-to-over-1-year-highs-oil-surges-to-70-as-russia-fires-intercontinental-ballistic-missile-to-ukraine" rel="noreferrer noopener">Natural Gas Prices Spike To Over 1-Year Highs, Oil Surges To $70 As Ukraine Says Intercontinental Ballistic Missile Fired By Russia</a>
This collaboration builds on Rivian&#8217;s previous partnership with XPEL, where the company offered full-body PPF on select models at the factory. The extended program aims to give owners greater protection and customization options, enhancing their Rivian ownership experience.
To participate, U.S. and Canadian customers can order and schedule installation via Rivian&#8217;s Gear Shop or XPEL&#8217;s website.
Price Action: RIVN shares are trading higher by 0.40% to $10.09 at last check Thursday.
Photo by Tada Images on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42111748/super-micro-computer-stock-is-rallying-thursday-whats-going-on" target="_blank" rel="noreferrer noopener">Super Micro Computer Stock Is Rallying Thursday: What&#8217;s Going On?</a></li>
</ul>

Movers

RIVN

XPEL

Rivian Automotive Expands Collaboration With XPEL: Details

CRGO

Freightos shares are trading higher after the company announced the official launch of its integration with e2open.

Shares of Target Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) recovered slightly in early trading on Thursday, after tanking on the company's <a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42106249/target-says-shoppers-wait-for-deals-a-day-after-rival-walmart-credits-market-gains-to-wealthy-households-tgt-edges-up-marginally-in-thursday-premarket">third-quarter earnings miss</a>.
<ul>
<li>JPMorgan <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/584847d9ee7bf6000154d225/christopher-horvers">analyst Christopher Horvers</a> maintained a Neutral rating, while slashing the price target from $167 to $139.</li>
<li>Goldman Sachs <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58580bcbee7bf60001bcfa29/kate-mcshane">analyst Kate McShane</a> reiterated a Buy rating, while reducing the price target from $192 to $164.</li>
<li>Piper Sandler <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/61d8398a2925770001ed33b1/alexia-dogani">analyst Alexia Morgan</a> reaffirmed a Neutral rating, while cutting the price target from $156 to $130.</li>
<li>KeyBanc Capital Markets <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/59009b5a0bd9910001e5f2aa/bradley-thomas">analyst Bradley Thomas</a> maintained a Sector Weight rating on the stock. </li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
JPMorgan: Target's third-quarter comps of 0.3% came significantly below the consensus of 1.4%, "as weather, continued weakness in discretionary categories, and some share loss continue to weigh on discretionary spend," Horvers said in a note. Markdowns and promotions represented "the lion's share" of the company's third-quarter gross margin miss and is "the big driver of the implied drop in 4Q gross margins," he added.
"We believe TGT continues to face share issues of varying degrees across all categories, sans beauty, but the trend appears to be improving," the analyst wrote. The stock got battered after the earnings release and is likely to bounce bank, he further stated.
Goldman Sachs: Target's disappointing comps were due to a decline in ticket size, with consumers continuing to spend cautiously, "most notably in discretionary categories," McShane said. The company's beauty segment bucked the trend and delivered comps of more than 6%, while food &amp; beverage and essentials delivered low single-digit growth, she added.
Target's gross margin contracted by around 20 basis points to 27.2% and came in below consensus, the analyst stated. "We would note this was the most significant change for the quarter as 2Q gross margins were up ~190 bps," she further wrote.
Piper Sandler: "While part of the Q3 miss can be attributed to transitory factors surrounding supply chain costs and discretionary sales weakness (apparel, home, etc.), results also suggest some ongoing share loss," Morgan wrote in a note. The company's gross margin came in at 27.2%, significantly short of consensus of 28.5%, she added.
Target's performance hinges on a recovery in discretionary consumer spending and, once this happens, the company's fundamentals are likely to improve, the analyst stated. "However, we now have increased concerns with tariff dynamics and how they could impact supply chain and sourcing costs in 2025 &#8211; particularly considering today&#8217;s margin miss was partly from navigating port strikes," she further wrote.
KeyBanc Capital Markets: Target's third-quarter results missed expectations due to "slower sales and unexpected margin pressure," Thomas said. Lower ticket sizes weighed on comps, which came well below expectations, he added.
Given the disappointing third-quarter performance and soft expectations for the fourth quarter, management lowered their 2024 guidance for comps and earnings below consensus, the analyst stated. "Looking ahead, we see consumer headwinds, competitive pressures, and moderating margin opportunities as potentially limiting upside for shares," he further wrote.
Price Action: Shares of Target had declined by 0.62% to $122.51 at the time of publication on Thursday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/earnings-beats/24/11/42100904/target-plunges-21-while-williams-sonoma-soars-27-on-same-day">Target Plunges 21% While Williams-Sonoma Soars 27% On Same Day</a></li>
</ul>
Image: Shutterstock

Earnings Beats

Reiteration

Target Posts Q3 Earnings Miss: Analysts Slash Forecasts On Market Share Loss, Margin Concerns

CLIR

ClearSign Technologies shares are trading higher after the company reported better-than-expected Q3 financial results.

Comerica Bank Extends Services For Direct Express Program By Three Years To Ensure Smooth Transition To New Treasury-Selected Financial Agent, Serving 3.4M Cardholders Since 2008

BLZE

Backblaze shares are trading lower. The company announced it upsized its share offering by $5 million to $35 million.

TD Cowen analyst Shaul Eyal maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Buy and raises the price target from $400 to $420.

PANW

TD Cowen Maintains Buy on Palo Alto Networks, Raises Price Target to $420

Amazon Likely To Be Investigated Under EU's Digital Markets Act Next Year; EU Antitrust Regulators Building Case For Amazon Investigation; Incoming EU Antitrust Chief Ribera To Decide On Timing, Whether To Go Ahead With Probe

Exxon Mobil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) plans to invest over $200 million to expand advanced recycling operations at its Baytown <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42109739/exxonmobil-to-expand-advanced-recycling-capacity" rel="noreferrer noopener">and Beaumont facilities in Texas</a>.
The expansions, set to begin in 2026, aim to boost recycling rates and reduce plastic waste in landfills.
The company also intends to add more units to achieve a global recycling capacity of 1 billion pounds annually by 2027.
ExxonMobil's investment will add 350 million pounds of advanced recycling capacity annually at its Baytown and Beaumont facilities, increasing its total capacity to 500 million pounds per year.
The company aims to develop additional projects across North America, Europe, and Asia, targeting 1 billion pounds of global recycling capacity by 2027.
This process complements traditional recycling by converting plastic waste into raw materials for products like fuels, lubricants, chemicals, and plastics, effectively addressing waste that mechanical recycling cannot process.
ExxonMobil&#8217;s first advanced recycling facility in Baytown, launched in 2022, is among the largest in North America, processing over 70 million pounds of plastic waste as of October 2024.
Karen McKee, president of ExxonMobil Product Solutions, said, &#8220;At our Baytown site, we&#8217;ve proven advanced recycling works at scale, which gives us confidence in our ambition to provide the capacity to process more than 1 billion pounds of plastic per year around the world.&#8221;
&#8220;The world&#8217;s plastic waste challenge will be solved with innovation, collaboration, and supportive government policy to improve waste management and circularity.&#8221;
Yesterday, the company inked a non-binding MOU for a multiyear agreement with&nbsp;LG Chem, a&nbsp;chemical company with a&nbsp;<a target="_blank" href="https://www.benzinga.com/news/contracts/24/11/42087743/exxon-mobils-lithium-leap-100000-metric-tons-to-fuel-lg-chems-us-plant" rel="noreferrer noopener">diversified business portfolio</a>.
ExxonMobil will supply up to 100,000 metric tons of lithium carbonate from its planned U.S. project to LG Chem's upcoming cathode plant in Tennessee, which is set to be the largest in the U.S.
Investors can gain exposure to XOM via&nbsp;EA Series Trust Strive U.S. Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRLL#NYSE">DRLL</a>) and&nbsp;Vanguard Energy Index Fund ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VDE#NYSE">VDE</a>).
Price Action: XOM shares are up 1.63% at $122.28 at the last check Thursday.
Photo: Del Henderson Jr. via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com//node/42113855" target="_blank" rel="noreferrer noopener">Breaking New Ground In OLED: Applied Materials Unveils MAX OLED Solution For Bigger Displays</a></li>
</ul>

DRLL

ExxonMobil Plans $200 Million Expansion To Tackle Plastic Waste: Details

TD Cowen analyst J. Derrick Wood maintains GitLab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTLB#NASDAQ">GTLB</a>) with a Buy and raises the price target from $63 to $70.

GTLB

TD Cowen Maintains Buy on GitLab, Raises Price Target to $70

To gain an edge, this is what you need to know today.
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2024/11/2024-11-21_08h52_20.png" alt="" style="width:624px" /></figure>
<h3 class="wp-block-heading">Nvidia Dips Aggressively Bought</h3>
Please <a href="https://thearorareport.com/chart-analysis-stock-nvidia-earnings-nvda-mc-11212024">click here</a> for an enlarged chart of NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>).
Note the following:
<ul>
<li>This article is about the big picture, not an individual stock.&nbsp; The chart of NVDA stock is being used to illustrate the point. As full disclosure, NVDA is part of The Arora Report&#8217;s ZYX Buy Model Portfolio.</li>
<li>The chart shows the dip in NVDA stock has been aggressively bought.</li>
<li>The chart shows that NVDA stock dipped into the support zone after earnings.&nbsp; The buying in NVDA this morning has been extremely aggressive as illustrated by the fact that NVDA traded as high as $149.40 vs. the prior high of $149.77.</li>
<li>The chart shows the NVDA bounced from the support zone to the resistance zone.</li>
<li>As of this writing, NVDA stock is very volatile.</li>
<li>In The Arora Report analysis, a tell for the stock market will be to see if NVDA stock breaks out or retraces back to the support zone.</li>
<li>Nvidia reported earnings better than the consensus numbers, better than some whisper numbers, but less than the top end of the whisper numbers.</li>
<li>Overheating was a big concern going into earnings.&nbsp; It appears that most of the overheating issues have been resolved.&nbsp; Here are the key points from Nvidia earnings:
<ul>
<li>Nvidia CEO Jensen Huang said, "The age of AI is in full steam, propelling a global shift to Nvidia computing."</li>
<li>Blackwell demand is likely to exceed supply in FY26.</li>
<li>Hopper demand is also very strong.</li>
<li>Nvidia is working on the next data center architecture that will improve production yields.</li>
<li>Nvidia expects enterprise AI, industrial AI, and robotics to continue to increase.</li>
<li>Nvidia beat on revenue.
<ul>
<li>Data center revenue and automotive revenue hit records.</li>
<li>Gaming revenue increased 15% from last year.</li>
<li>Professional visualization revenue increased 17% from last year.</li>
</ul>
</li>
</ul>
</li>
<li>The fact that NVDA dips are being aggressively bought is helping the overall stock market.</li>
<li>Also helping the stock market this morning is Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) approaching $100K.</li>
<li>Sentiment is extremely positive.</li>
<li>Investors are buying stocks and cryptos with total abandon.&nbsp; If it was not for the positive seasonality and year end chase, this kind of reckless buying would have resulted in increasing the protection band because extreme positive sentiment is historically a sell signal.&nbsp; However, The Arora Report call remains to buy the dips because the year end chase is likely to trump all other factors.&nbsp; In year end chase, even bearish money managers aggressively buy stocks to keep up with their benchmarks.</li>
<li>Initial jobless claims came at 213K vs. 221K consensus.&nbsp; This indicates that the job market is very strong.&nbsp; This is another data point that shows that the Fed should not have been cutting interest rates as aggressively as it did. In the short term, the Fed's actions have poured gasoline over the fire to aggressively buy stocks and cryptos.</li>
</ul>
<h3 class="wp-block-heading">First ICBM Fired</h3>
The first operational intercontinental ballistic missile (ICBM) was developed by Russia in 1957, followed by development by the U.S. in 1959.&nbsp; To the best of our knowledge, Russia has fired the first ICBM in battle since its invention.&nbsp; This is Russia's response to Ukraine firing U.S. and British long range missiles on Russian territory.
In The Arora Report analysis, both Russia and Ukraine are escalating the conflict to gain an advantage before Trump stops the war.&nbsp; These developments have major implications for investors.&nbsp;
<h3 class="wp-block-heading">Problem For India</h3>
Gautam Adani is the most important industrialist in India.&nbsp; He is also very closely allied with India&#8217;s Prime Minister Modi.&nbsp; The U.S. Department of Justice has just indicted Adani for bribes in solar contracts.
The Indian stock market has fallen on the news.  In The Arora Report analysis, some foreign money is going to flow out of India on this development.  The Arora Report call has been to steadily take partial profits on India positions Fairfax India Holdings Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/FFXDF#OTC">FFXDF</a>), WisdomTree India Earnings Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPI#NYSE">EPI</a>), iShares MSCI India Small-Cap ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/SMIN#BATS">SMIN</a>), and VanEck India Growth Leaders ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLIN#NYSE">GLIN</a>).  The Arora Report&#8217;s call yesterday evening was to take more partial profits on India positions.
<h3 class="wp-block-heading">Magnificent Seven Money Flows</h3>
In the early trade, money flows are positive in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), and NVDA.
In the early trade, money flows are neutral in Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
In the early trade, money flows are negative in Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>).
In the early trade, money flows are positive in SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h3 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h3>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).  The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).  The most popular ETF for oil is United States Oil ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>).
<h3 class="wp-block-heading">Bitcoin</h3>
Bitcoin is approaching $100K.
<h3 class="wp-block-heading">Protection Band And What To Do Now</h3>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h3 class="wp-block-heading">Traditional 60/40 Portfolio</h3>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

AAPL

FFXDF

GLIN

GOOG

MSFT

SMIN

TSLA

Nvidia Aggressively Bought, Russia Fires First Intercontinental Ballistic Missile, Adani Indicted

Comments

Immunome

News

Latest news for Immunome (NASDAQ:IMNM) Stock

People Also Watch

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga